Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. [electronic resource]
Producer: 20120905Description: 1-410 p. digitalISSN:- 2046-4924
- Benzamides
- Blast Crisis -- drug therapy
- Clinical Trials as Topic
- Cost-Benefit Analysis
- Dasatinib
- Decision Support Techniques
- Disease Progression
- Drug Resistance, Neoplasm
- Health Care Costs -- statistics & numerical data
- Humans
- Imatinib Mesylate
- Incidence
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Leukemia, Myeloid, Accelerated Phase -- drug therapy
- Leukemia, Myeloid, Chronic-Phase -- drug therapy
- Models, Economic
- Piperazines -- pharmacology
- Prognosis
- Protein Kinase Inhibitors -- economics
- Pyrimidines -- economics
- Quality of Life
- Thiazoles -- economics
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review; Systematic Review
There are no comments on this title.
Log in to your account to post a comment.